NCT04633252 2026-01-16
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
26 trialsNCT03218826 2025-10-30
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03517969 2025-10-20
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02649855 2024-08-06
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00032825 2019-11-21
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01683994 2019-11-08
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00527124 2018-08-09
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01145508 2017-09-19
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00058253 2014-06-17
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00110214 2014-05-09
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002775 2014-01-06
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003633 2013-12-19
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00005960 2013-12-04
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00376792 2013-08-26
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00796458 2013-08-12
Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005627 2013-07-18
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00255606 2013-06-26
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00045227 2013-06-19
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016107 2013-06-05
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00046826 2013-04-04
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00074022 2013-01-24
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00083005 2012-03-15
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
National Institutes of Health Clinical Center (CC)
Phase 2 Completed